GLP-1 RAs reduce weight and muscle mass, but not diet quality or cravings in real-world use
Background
Obesity is a complex chronic disease with significant health implications, and while GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide have demonstrated potent weight loss efficacy, their real-world impact on specific dietary behaviors, food cravings, and body composition beyond fat loss remains less understood. Current weight loss interventions often overlook the quality of dietary intake and the preservation of skeletal muscle mass, which is crucial for metabolic health. This study addresses the gap by observing these changes in a clinical setting without structured nutritional support.
Study Design
This prospective observational study followed n=28 adults with obesity initiating semaglutide or tirzepatide OMM therapy for 24 weeks. Participants received no structured nutrition intervention. Dietary intake was assessed via food records, and diet quality was quantified using the Healthy Eating Index (HEI-2020). Food cravings were measured with the Food Cravings Inventory-III questionnaire. Body composition, including estimated skeletal muscle mass, was evaluated using bioelectrical impedance analysis.
Results
GLP-1 RA therapy led to significant reductions in body weight, adiposity, and estimated skeletal muscle mass (all P < 0.001). Approximately one-quarter of the total weight loss was attributable to estimated skeletal muscle mass. Total energy intake decreased significantly, with parallel reductions across all macronutrients. Higher absolute protein intake was associated with greater preservation of estimated skeletal muscle mass (r = 0.41, P = 0.0498). Diet quality, as measured by HEI-2020, did not significantly improve, and overall food cravings remained unchanged. However, individuals with higher baseline cravings experienced greater reductions over time (r = -0.69, P < 0.001). Significant declines in intake were also observed across multiple micronutrients.
The study highlights that roughly 25% of weight lost on GLP-1 RAs in a real-world setting without dietary guidance may be muscle mass, underscoring the need for strategic nutritional support.
Key Findings
- GLP-1 RA therapy significantly reduced body weight, adiposity, and estimated skeletal muscle mass (all P < 0.001).
- Approximately 25% of total weight loss was attributed to estimated skeletal muscle mass.
- Diet quality did not significantly improve, and overall food cravings remained unchanged.
- Higher baseline food cravings were associated with greater reductions over time (r = -0.69, P < 0.001).
- Higher absolute protein intake correlated with greater preservation of estimated skeletal muscle mass (r = 0.41, P = 0.0498).
Why It Matters
This study underscores a critical consideration for individuals using GLP-1 RAs for weight loss: while effective, the therapy alone may not improve diet quality or reduce cravings, and a significant portion of weight lost can be muscle mass. For peptide users and biohackers, this implies that simply taking a GLP-1 RA without concurrent attention to high protein intake and overall dietary quality could lead to suboptimal body composition changes. The finding that higher protein intake correlated with muscle preservation is a key actionable takeaway, suggesting that a focused nutritional strategy, perhaps including protein supplementation, is crucial to maximize fat loss while minimizing muscle catabolism. This moves beyond just 'eat less' to 'eat smarter' when on these powerful medications.
semaglutide
tirzepatide
glp-1-agonist
gip-agonist
obesity
weight-loss